A5055115542- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- Myasthenia Gravis and Thymoma
- Cancer Immunotherapy and Biomarkers
- Genetic factors in colorectal cancer
- Breast Cancer Treatment Studies
- Mechanisms of cancer metastasis
- Esophageal and GI Pathology
- HER2/EGFR in Cancer Research
- Histone Deacetylase Inhibitors Research
- Occupational and environmental lung diseases
- Palliative Care and End-of-Life Issues
- Frailty in Older Adults
- Glioma Diagnosis and Treatment
- Cancer Mechanisms and Therapy
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Angiogenesis and VEGF in Cancer
- Neuroblastoma Research and Treatments
- Pleural and Pulmonary Diseases
- Cancer-related Molecular Pathways
- Advanced Breast Cancer Therapies
- Autophagy in Disease and Therapy
- Chromatin Remodeling and Cancer
Humanitas University
2022
Istituti di Ricovero e Cura a Carattere Scientifico
2022
IRCCS Humanitas Research Hospital
2019-2022
Humanitas Gavazzeni
2022
University of Insubria
2018-2019
University of Milano-Bicocca
2018
ASST Melegnano e della Martesana
2016
Azienda Ospedaliera San Gerardo
2016
Background Angiogenesis has an important role in thymic epithelial tumors (TETs). Regorafenib inhibits vascular endothelial growth factor receptors (VEGFRs), platelet‐derived receptor β (PDGFR‐β), and fibroblast (FGFRs). This study explored the activity of regorafenib as monotherapy patients with advanced or recurrent B2‐B3 thymoma (T) carcinoma (TC) previously treated platinum‐containing chemotherapy. Methods A Fleming single‐arm, single‐stage, phase 2 trial to evaluate (160 mg once a day...
Triple Negative Breast Cancer (TNBC) is an aggressive neoplasia with median Overall Survival (OS) less than two years. Despite the availability of new drugs, chance survival these patients did not increase. The combination low doses drugs in a metronomic schedule showed efficacy clinical trials, exhibiting anti-proliferative and anti-tumour activity. In Victor-2 study we recently evaluated (mCHT) Capecitabine (CAPE) Vinorelbine (VNR) breast cancer showing disease control rate...
Purpose Elderly patients with metastatic breast cancer are expected to derive similar benefits from chemotherapy as younger patients, but more likely experience therapy-related toxicity. Data the VICTOR-1 study showed that metronomic therapy vinorelbine and capecitabine was effective well tolerated in cancer. This analysis determined efficacy safety of combination oral a subgroup aged ≥70 years. Methods Eighteen 32 enrolled were Objective response clinical benefit rates calculated toxicity...
The main hypothesis of this study is that gene expression profiles (GEPs) integrating both tumor antigenicity and a pre-existing adaptive immune response can be used to generate distinct immune-related signatures BRAF mutant colorectal cancers (BRAF-CRCs) identify actionable biomarkers predicting immunotherapy. GEPs 89 immunotherapy-naïve BRAF-CRCs were generated using the Pan-Cancer IO 360 panel NanoString nCounter platform correlated with microsatellite instability (MSI) status CD8+...
Colorectal rhabdoid carcinomas (CRbCs) are very rare and aggressive cancers. The BRAF mutation CpG island methylator phenotype have been reported to be common features of CRbCs. This study reviews the literature about CRbCs analyzes clinicopathological molecular profiles seven characterized by large discohesive cells with abundant eosinophilic cytoplasm, showing hyaline inclusions rounded bean-shaped nuclei. For comparison, we included four poorly differentiated medullary (PDMCs) focal...
The paucity of the therapeutic armamentarium currently available for patients with malignant mesothelioma clearly represents a huge unmet need. Over last years, based on new advances in understanding biology mesothelioma, approaches have been investigated.In this manuscript, literature data regarding drug treatment are critically reviewed, focusing particularly immunotherapy and targeted therapy.The latest findings therapy changing mesothelioma. However, comprises genomically different...
e14014 Background: TNBC represents an important clinical challenge because of poor prognosis. One the emerging strategy to achieve disease control while reducing toxicity is metronomic chemotherapy (mCHT) which targets endothelial cells (ECs) and inhibits tumor growth. mVRL a promising option in patients (pts) with metastatic breast cancer (MBC), resulting median PFS 7.7 months OS 15.9. To better explain effect we studied effects doses VRL vitro models compared them standard same drug....
e15624 Background: BRAFV600E mutation occurs in less than 10% of colorectal cancers (BmutCRCs) and is a strong predictor poor prognosis not only metastatic setting. Although BmutCRCs are usually considered unique clinico-pathological entity, biological heterogeneity within this population has been recently described. Our aim was an extensive study multicentric series 74 with specific focus on the inflammatory profiles. Methods: cohort included BmutCRCs. At diagnosis 2/74 were stage I, 7/74...
65 Background: Cancer patients (pts) are often treated with anticancer therapy (CT) even in the last months of life and hospitalized through an access to emergency room (ERa). This is frequently time when a palliative care (PC) service starts, or pts die. Methods: We performed retrospective analysis admitted our Oncology Unit ERa. evaluated: pts’ characteristics, histology, date diagnosis, sites metastases, comorbidities, previous CT radiotherapy (RT), imaging procedures other exams 90 days...